Dry Age-Related Macular Degeneration Market Size, Share, Growth, and Industry Analysis, By Types (Oral, Injectables), By Applications (Above 40 Years, Above 60 Years, Above 75 Years), and Regional Insights and Forecast to 2034

Detailed TOC of Global Dry Age-Related Macular Degeneration Market Research Report 2025

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dry Age-Related Macular Degeneration Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Oral
1.2.3 Injectables
1.3 Market by Application
1.3.1 Global Dry Age-Related Macular Degeneration Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Above 40 Years
1.3.3 Above 60 Years
1.3.4 Above 75 Years
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dry Age-Related Macular Degeneration Market Perspective (2018-2033)
2.2 Dry Age-Related Macular Degeneration Growth Trends by Region
2.2.1 Global Dry Age-Related Macular Degeneration Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Dry Age-Related Macular Degeneration Historic Market Size by Region (2018-2025)
2.2.3 Dry Age-Related Macular Degeneration Forecasted Market Size by Region (2024-2033)
2.3 Dry Age-Related Macular Degeneration Market Dynamics
2.3.1 Dry Age-Related Macular Degeneration Industry Trends
2.3.2 Dry Age-Related Macular Degeneration Market Drivers
2.3.3 Dry Age-Related Macular Degeneration Market Challenges
2.3.4 Dry Age-Related Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dry Age-Related Macular Degeneration Players by Revenue
3.1.1 Global Top Dry Age-Related Macular Degeneration Players by Revenue (2018-2025)
3.1.2 Global Dry Age-Related Macular Degeneration Revenue Market Share by Players (2018-2025)
3.2 Global Dry Age-Related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dry Age-Related Macular Degeneration Revenue
3.4 Global Dry Age-Related Macular Degeneration Market Concentration Ratio
3.4.1 Global Dry Age-Related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dry Age-Related Macular Degeneration Revenue in 2022
3.5 Dry Age-Related Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Dry Age-Related Macular Degeneration Product Solution and Service
3.7 Date of Enter into Dry Age-Related Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dry Age-Related Macular Degeneration Breakdown Data by Type
4.1 Global Dry Age-Related Macular Degeneration Historic Market Size by Type (2018-2025)
4.2 Global Dry Age-Related Macular Degeneration Forecasted Market Size by Type (2024-2033)
5 Dry Age-Related Macular Degeneration Breakdown Data by Application
5.1 Global Dry Age-Related Macular Degeneration Historic Market Size by Application (2018-2025)
5.2 Global Dry Age-Related Macular Degeneration Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Dry Age-Related Macular Degeneration Market Size (2018-2033)
6.2 North America Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Dry Age-Related Macular Degeneration Market Size by Country (2018-2025)
6.4 North America Dry Age-Related Macular Degeneration Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dry Age-Related Macular Degeneration Market Size (2018-2033)
7.2 Europe Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Dry Age-Related Macular Degeneration Market Size by Country (2018-2025)
7.4 Europe Dry Age-Related Macular Degeneration Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dry Age-Related Macular Degeneration Market Size (2018-2033)
8.2 Asia-Pacific Dry Age-Related Macular Degeneration Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Region (2018-2025)
8.4 Asia-Pacific Dry Age-Related Macular Degeneration Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dry Age-Related Macular Degeneration Market Size (2018-2033)
9.2 Latin America Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Dry Age-Related Macular Degeneration Market Size by Country (2018-2025)
9.4 Latin America Dry Age-Related Macular Degeneration Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dry Age-Related Macular Degeneration Market Size (2018-2033)
10.2 Middle East & Africa Dry Age-Related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2018-2025)
10.4 Middle East & Africa Dry Age-Related Macular Degeneration Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Santen Pharmaceuticals
11.1.1 Santen Pharmaceuticals Company Detail
11.1.2 Santen Pharmaceuticals Business Overview
11.1.3 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Introduction
11.1.4 Santen Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.1.5 Santen Pharmaceuticals Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Dry Age-Related Macular Degeneration Introduction
11.2.4 Allergan Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.2.5 Allergan Recent Development
11.3 Bausch Health
11.3.1 Bausch Health Company Detail
11.3.2 Bausch Health Business Overview
11.3.3 Bausch Health Dry Age-Related Macular Degeneration Introduction
11.3.4 Bausch Health Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.3.5 Bausch Health Recent Development
11.4 Alimera Science
11.4.1 Alimera Science Company Detail
11.4.2 Alimera Science Business Overview
11.4.3 Alimera Science Dry Age-Related Macular Degeneration Introduction
11.4.4 Alimera Science Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.4.5 Alimera Science Recent Development
11.5 Phio Pharmaceuticals
11.5.1 Phio Pharmaceuticals Company Detail
11.5.2 Phio Pharmaceuticals Business Overview
11.5.3 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Introduction
11.5.4 Phio Pharmaceuticals Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.5.5 Phio Pharmaceuticals Recent Development
11.6 Ocumension Therapeutics
11.6.1 Ocumension Therapeutics Company Detail
11.6.2 Ocumension Therapeutics Business Overview
11.6.3 Ocumension Therapeutics Dry Age-Related Macular Degeneration Introduction
11.6.4 Ocumension Therapeutics Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.6.5 Ocumension Therapeutics Recent Development
11.7 Belite Bio
11.7.1 Belite Bio Company Detail
11.7.2 Belite Bio Business Overview
11.7.3 Belite Bio Dry Age-Related Macular Degeneration Introduction
11.7.4 Belite Bio Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.7.5 Belite Bio Recent Development
11.8 Kubota Vision
11.8.1 Kubota Vision Company Detail
11.8.2 Kubota Vision Business Overview
11.8.3 Kubota Vision Dry Age-Related Macular Degeneration Introduction
11.8.4 Kubota Vision Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.8.5 Kubota Vision Recent Development
11.9 Iveric Bio
11.9.1 Iveric Bio Company Detail
11.9.2 Iveric Bio Business Overview
11.9.3 Iveric Bio Dry Age-Related Macular Degeneration Introduction
11.9.4 Iveric Bio Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.9.5 Iveric Bio Recent Development
11.10 Eyestem Research
11.10.1 Eyestem Research Company Detail
11.10.2 Eyestem Research Business Overview
11.10.3 Eyestem Research Dry Age-Related Macular Degeneration Introduction
11.10.4 Eyestem Research Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.10.5 Eyestem Research Recent Development
11.11 Y2 Solution
11.11.1 Y2 Solution Company Detail
11.11.2 Y2 Solution Business Overview
11.11.3 Y2 Solution Dry Age-Related Macular Degeneration Introduction
11.11.4 Y2 Solution Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.11.5 Y2 Solution Recent Development
11.12 Stealth Biotherapeutics
11.12.1 Stealth Biotherapeutics Company Detail
11.12.2 Stealth Biotherapeutics Business Overview
11.12.3 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Introduction
11.12.4 Stealth Biotherapeutics Revenue in Dry Age-Related Macular Degeneration Business (2018-2025)
11.12.5 Stealth Biotherapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details